Limitations of AI Models in Drug Design
Researchers at the University of Basel have found that AI models for drug design, such as AlphaFold or RosettaFold, have a significant limitation: they only memorize patterns, rather than understanding physical relationships.
These models often fail when it comes to new proteins that are of particular interest for innovative drugs. Proteins play a crucial role in medicine, serving as active ingredients or target structures for drugs.
The development of new therapies typically starts with deciphering the three-dimensional structure of proteins. Machine learning has simplified this process, but the lack of understanding of physical relationships hinders the discovery of new drugs.
The first step in developing new therapies is therefore usually to decipher the three-dimensional structure of proteins.
- Proteins serve as active ingredients, such as enzymes or antibodies.
- Proteins are target structures for drugs.
The developers of these AI models received the Nobel Prize in Chemistry in 2024.
Author's summary: AI models for drug design have limitations in understanding physical relationships.
More News
- Republicans lose ground in Tennessee special election
- IPL Auction 2025
- 10 Slow-Paced Towns In Idaho Where You Can Live Peacefully, Happily, And Debt-Free
- Skippylongstocking excels in Harlan’s Holiday Stakes
- Sunny Days Ahead as Tampa Enjoys Mild Temperatures
- Gill Cleared! Gambhir Says He's Ready to Go
- Evidence of burial ground at Tuam mother and baby home
- Teleperformance Shares Advance 3.39% at Opening
- Suryakumar Yadav Becomes Mumbai's Highest T20 Run-Scorer
- Breeze adding new nonstop flights from Long Island to Myrtle Beach